Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators.

Bunch TJ, Anderson JL.

Am J Cardiovasc Drugs. 2014 Apr;14(2):89-100. doi: 10.1007/s40256-013-0056-x. Review.

PMID:
24288157
2.
3.

Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.

Bollmann A, Husser D, Cannom DS.

Am J Cardiovasc Drugs. 2005;5(6):371-8. Review.

PMID:
16259525
4.

Antiarrhythmic and nonantiarrhythmic drugs for sudden cardiac death prevention.

Das MK, Zipes DP.

J Cardiovasc Pharmacol. 2010 May;55(5):438-49. Review.

PMID:
20509177
5.

Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.

Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.

J Cardiovasc Electrophysiol. 2012 Mar;23(3):296-301. doi: 10.1111/j.1540-8167.2011.02183.x. Epub 2011 Sep 28.

PMID:
21955243
6.

A benefit-risk assessment of class III antiarrhythmic agents.

Elming H, Brendorp B, Pehrson S, Pedersen OD, Køber L, Torp-Petersen C.

Expert Opin Drug Saf. 2004 Nov;3(6):559-77. Review.

PMID:
15500415
7.

Comparison of beta-blockers, amiodarone plus beta-blockers, or sotalol for prevention of shocks from implantable cardioverter defibrillators: the OPTIC Study: a randomized trial.

Connolly SJ, Dorian P, Roberts RS, Gent M, Bailin S, Fain ES, Thorpe K, Champagne J, Talajic M, Coutu B, Gronefeld GC, Hohnloser SH; Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators.

JAMA. 2006 Jan 11;295(2):165-71.

PMID:
16403928
8.

Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.

Hilleman DE, Bauman AL.

Pharmacotherapy. 2001 May;21(5):556-75. Review.

PMID:
11349745
9.

New advances in class III antiarrhythmic drug therapy.

Sager PT.

Curr Opin Cardiol. 2000 Jan;15(1):41-53. Review.

PMID:
10666660
10.

Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.

Bunch TJ, Mahapatra S, Murdock D, Molden J, Weiss JP, May HT, Bair TL, Mader KM, Crandall BG, Day JD, Osborn JS, Muhlestein JB, Lappe DL, Anderson JL.

Pacing Clin Electrophysiol. 2011 Dec;34(12):1600-6. doi: 10.1111/j.1540-8159.2011.03208.x. Epub 2011 Sep 3.

PMID:
21895727
11.

Role of drug therapy for sustained ventricular tachyarrhythmias.

Mitchell LB.

Cardiol Clin. 2008 Aug;26(3):405-18, vi. doi: 10.1016/j.ccl.2008.03.004. Review.

PMID:
18538187
12.

Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center.

Rajawat YS, Patel VV, Gerstenfeld EP, Nayak H, Marchlinski FE.

Pacing Clin Electrophysiol. 2004 Dec;27(12):1670-81. No abstract available.

PMID:
15613132
13.

Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.

Kowey PR, Crijns HJ, Aliot EM, Capucci A, Kulakowski P, Radzik D, Roy D, Connolly SJ, Hohnloser SH; ALPHEE Study Investigators.

Circulation. 2011 Dec 13;124(24):2649-60. doi: 10.1161/CIRCULATIONAHA.111.072561. Epub 2011 Nov 14.

14.

Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy.

Droogan C, Patel C, Yan GX, Kowey PR.

Heart Fail Clin. 2011 Apr;7(2):195-205, viii. doi: 10.1016/j.hfc.2010.12.003. Review.

PMID:
21439498
15.

Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.

Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM; SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators.

Circulation. 2004 Dec 14;110(24):3646-54. Epub 2004 Nov 8.

16.

Drugs or implantable cardioverter-defibrillators in patients with poor left ventricular function?

Block M, Hammel D, Böcker D, Borggrefe M, Breithardt G.

Am J Cardiol. 1996 Sep 12;78(5A):62-8. Review.

PMID:
8820838
17.

[Antiarrhythmic therapy in patients with heart failure].

Faber TS, Zehender M.

Ther Umsch. 2000 May;57(5):324-32. Review. German.

PMID:
10859993
18.

Effect of concomitant antiarrhythmic therapy on survival in patients with implantable cardioverter defibrillators.

Ho AT, Pai SM, Timothy P, Pai RG.

Pacing Clin Electrophysiol. 2005 Jul;28(7):647-53.

PMID:
16008799
19.

New antiarrhythmic drugs for the treatment of atrial fibrillation.

Castro A, Bianconi L, Santini M.

Pacing Clin Electrophysiol. 2002 Feb;25(2):249-59. Review. No abstract available.

PMID:
11916001
20.

Supplemental Content

Support Center